Allegheny Financial Group LTD purchased a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 1,698 shares of the company’s stock, valued at approximately $224,000. Several other hedge funds and other institutional investors have also […]
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price upped by Canaccord Genuity Group from $154.00 to $164.00 in a research note issued to investors on Thursday, Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock. NBIX has been the subject of a number of other reports. Barclays upped their […]
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price increased by Citigroup from $140.00 to $150.00 in a research report released on Friday, Benzinga reports. The firm currently has a neutral rating on the stock. Other analysts also recently issued research reports about the company. Oppenheimer raised their price objective on Neurocrine Biosciences from […]
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price increased by Oppenheimer from $200.00 to $216.00 in a research report report published on Thursday morning, Benzinga reports. The firm currently has an outperform rating on the stock. Several other equities analysts have also weighed in on the company. Wells Fargo & Company upgraded Neurocrine […]
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective hoisted by Oppenheimer from $200.00 to $216.00 in a research note issued to investors on Thursday morning, Benzinga reports. Oppenheimer currently has an outperform rating on the stock. Other equities research analysts have also issued reports about the company. Citigroup reduced their price objective on […]